Unsplash+FinancingImmutrin secures £65m Series A for amyloid-removing heart therapyImmutrin, a UK biotech, has raised £65m (€75m) in Series A funding for a pioneering antibody designed to remove pre-existing amyloid deposits in amyloidosis. more ➔
RocheOrganoids and Lab-on-chipOrganoids: new Roche research centre in Basel will focus on alternative model systemsAnimal testing or organoids—this question is increasingly being answered in favour of organoids. Yet robust model systems still require further research and, crucially, validation. More large pharmaceutical … more ➔
Picture by Joanna Kosinska via UnsplashLicencingSanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali TherapeuticsSanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated … more ➔
Unsplash+FinancingDutch biotech Laigo Bio bags €17m in oversubscribed seed roundMembrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s … more ➔
adobe stock photos - Michael Derrer Fuchs SwitzerlandNovartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapyNovartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD … more ➔
adobe stock photos - Sundry Photography RocheSwiss Roche builds its own AI factory with NVIDIA – with Genentech in CaliforniaThe Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that … more ➔
FundraisingMestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinicUK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares … more ➔
adobe stock photos - deemerwhaIntracellular targetingDelivering drugs into cells: Seed funding for German iDEL and its ‘wonder shuttle’The new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, … more ➔
AITernary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory diseaseLondon-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, … more ➔
AIOwkin spins out AI diagnostics startup Waiv with $33M financingFrench AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision … more ➔
Unsplash+
Roche
Picture by Joanna Kosinska via Unsplash
Unsplash+
adobe stock photos - Michael Derrer Fuchs 
adobe stock photos - Sundry Photography 
adobe stock photos - deemerwha
